Our Pipeline

Unveiling the Potential of the Ta:RNA™ Platform

We believe that our Ta:RNA™ platform can transform outcomes for a wide range of cancer patients.

Our Ta:RNA™ development programme is initially focused on three key receptor targets with our TAR001, TAR002 and TAR003 molecules.

Survival rates image

Our lead Ta:RNA™-based molecule, TAR001, is the first in a new class of targeted apoptosis and immune modulators (TAIMs).

TargImmune development programme

TAR001 targets the epidermal growth factor receptor (EGFR) to deliver Poly-IC, a synthetic dsRNA, to tumours which overexpress this receptor.

TAR001 is currently approaching Phase 1 clinical trials.

TargImmune Therapeutics chart